PMID- 26169181
OWN - NLM
STAT- MEDLINE
DCOM- 20160223
LR  - 20181202
IS  - 1872-6976 (Electronic)
IS  - 0167-4943 (Linking)
VI  - 61
IP  - 2
DP  - 2015 Sep-Oct
TI  - A randomized, controlled trial of effectiveness and safety of management of OAB 
      symptoms in elderly men and women with standard-dosed combination of solifenacin 
      and mirabegron.
PG  - 212-6
LID - S0167-4943(15)30010-8 [pii]
LID - 10.1016/j.archger.2015.06.006 [doi]
AB  - OBJECTIVES: Comparison of effectiveness and safety of solifenacin and mirabegron, 
      as well as their combination, for managing heavy symptoms of overactive bladder. 
      MATERIALS AND METHODS: All patients who participated in the examination (average 
      age: 71.2) were split into 4 groups. Patients included in Group capital A, Cyrillic (n=63) were 
      treated with mirabegron 50mg/day/6 weeks, in Group B (n=52)-with solifenacin 
      10mg/day/6 weeks, in Group capital ES, Cyrillic (n=65)-with the same doses of both drugs 
      simultaneously/6 weeks, and in Group D (n=59)-with placebo. Monitoring was 
      carried out using OAB-questionnaires, bladder diaries and urodynamic examination. 
      RESULTS: In elderly patients with initial frequency of episodes of incontinence 
      (EI)>/=3/day standard doses of mirabegron (50mg/day) and solifenacin 10mg/day 
      administered during 6 weeks result with the decrease in frequency of EI with high 
      correlation (r=0,74, p</=0.05); final results in both groups are significantly 
      different from initial value of p</=0.05. In the group, where patients were taking 
      both drugs simultaneously, final results significantly differ from both initial 
      values of the parameters in these groups (EI: 5.1-->1.6 per day, p</=0.01; urination: 
      9.1-->5.3 per day, p</=0.01; post-void residual 19.4-->29.9, p</=0.01) and final values 
      in Groups A and B (p</=0.05). The percentage of side effects in this group does not 
      significantly differ from that in the groups, where patients were receiving 
      monotherapy. CONCLUSION: Combined treatment for severe symptoms of OAB in elderly 
      men and women with standard doses of solifenacin and mirabegron provides 
      satisfactory therapeutic effect within short period of time without increasing 
      the risk of side effects, which undoubtedly improves quality of life and 
      self-esteem of patients. At the same time, taking any of these drugs separately 
      for the treatment of severe malfunction of lover urinary tracts in elderly people 
      may turn out to be insufficient for effective symptom management.
CI  - Copyright (c) 2015 Elsevier Ireland Ltd. All rights reserved.
FAU - Kosilov, Kirill
AU  - Kosilov K
AD  - School of Humanities, Far Eastern Federal University, Primorsky Region, Ayax 10, 
      F733 Vladivostok, Russian Federation. Electronic address: oton2000@mail.ru.
FAU - Loparev, Sergay
AU  - Loparev S
AD  - Department of Urology, City polyclinic No. 3, St. Lugovaya 55, Vladivostok, 
      Russian Federation. Electronic address: Lurd1973@mail.ru.
FAU - Ivanovskaya, Marina
AU  - Ivanovskaya M
AD  - Far Eastern Fisheries University, St. Lugovaya 52a, Vladivostok, Russian 
      Federation. Electronic address: marina.iwanowsckaya@yandex.ru.
FAU - Kosilova, Liliya
AU  - Kosilova L
AD  - Department of the Functional Methods of Examination, Med. Association No. 2 of 
      Vladivostok-sity, St. Prihodko 4a,Vladivostok, Russian Federation. Electronic 
      address: Lileka2@yandex.ru.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20150625
PL  - Netherlands
TA  - Arch Gerontol Geriatr
JT  - Archives of gerontology and geriatrics
JID - 8214379
RN  - 0 (Acetanilides)
RN  - 0 (Thiazoles)
RN  - 0 (Urological Agents)
RN  - KKA5DLD701 (Solifenacin Succinate)
RN  - MVR3JL3B2V (mirabegron)
SB  - IM
CIN - J Urol. 2016 Jun;195(6):1834. PMID: 27191090
MH  - Acetanilides/*administration & dosage/therapeutic use
MH  - Aged
MH  - Aged, 80 and over
MH  - Disease Management
MH  - Drug Therapy, Combination
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Quality of Life
MH  - Solifenacin Succinate/*administration & dosage/therapeutic use
MH  - Surveys and Questionnaires
MH  - Thiazoles/*administration & dosage/therapeutic use
MH  - Treatment Outcome
MH  - Urinary Bladder/*drug effects/physiopathology
MH  - Urinary Bladder, Overactive/diagnosis/*drug therapy
MH  - Urinary Incontinence
MH  - Urination
MH  - Urodynamics/drug effects
MH  - Urological Agents/*administration & dosage/adverse effects/therapeutic use
OTO - NOTNLM
OT  - Elderly
OT  - Mirabegron
OT  - Overactive bladder
OT  - Solifenacin
EDAT- 2015/07/15 06:00
MHDA- 2016/02/26 06:00
CRDT- 2015/07/15 06:00
PHST- 2014/11/19 00:00 [received]
PHST- 2015/06/09 00:00 [revised]
PHST- 2015/06/11 00:00 [accepted]
PHST- 2015/07/15 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2016/02/26 06:00 [medline]
AID - S0167-4943(15)30010-8 [pii]
AID - 10.1016/j.archger.2015.06.006 [doi]
PST - ppublish
SO  - Arch Gerontol Geriatr. 2015 Sep-Oct;61(2):212-6. doi: 
      10.1016/j.archger.2015.06.006. Epub 2015 Jun 25.